ACETATEFDA批准前列腺癌合用治疗新药美国上市激素抵抗性2011年4月28日,美国FDA批准Centocor Ortho生物科技公司的新药醋酸阿比特龙(通用名:Abiraterone Acetate,商品名:ZYTIGA)上市.该药获批的适应证为,与泼尼松合用治疗已经接受过含有多西他赛化疗方案的激素抵抗性前列腺癌(CRPC)患者.中国执业药师...
醋酸阿比特龙ZYTIGA|AbirateroneAcetate中文说明书 2018年2月7日,美国食品药品监督管理局(FDA)批准醋酸阿比特龙(ZYTIGA, Janssen Biotech Inc.)联合强的松片治疗转移性高风险性去势敏感前列腺癌(CSPC)。 FDA最初于2011年批准醋酸阿比特龙联合强的松治疗转移性去势耐药前列癌(CRPC),并于2012年扩大了转移性CRPC的适应症。
Abiraterone acetate is an oral, potent, selective, and irreversible inhibitor of CYP17. ChemeGen 作为优秀的抑制剂、激动剂及新型生命科学试剂的供应商,致力于为广大科研、商业实验室的科学研究者提供高品质的产品与技术服务,不断促进生命科学领域的新技术发展。 公司简介 ChemeGen 作为*的抑制剂、激动剂及新型...
美国FDA橙皮书数据库提供Abiraterone Acetate药品的详细信息,包括申请号212206,中文名称醋酸阿比特龙,商标名,剂型/给药途径,参比制剂,企业名称Teva Pharms Usa,批准日期等信息,以及Abiraterone Acetate的专利和市场独占信息的查询.
Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.|Abiraterone is a Cytochrome P450 17A1 Inhibitor. The mechanism of action of abiraterone is as a Cytochrome P450...
at 1-844-837-6511 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.DRUG INTERACTIONS CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during abiraterone acetate treatment. If a strong CYP3A4 inducer must be co-administered, increase the abiraterone acetate dosing frequency. (2.5, ...
of this trial is to determine the drug absorption of niclosamide in combination with abiraterone acetate and prednisone in patients with CRPC. Abiraterone in combination with prednisone has been approved by the FDA for the treatment of CRPC and metastatic castration-sensitive prostate cancer15,16,17...
This phase II open-label study evaluated the effect of concurrent or sequential administration of abiraterone acetate plus prednisone (AA + P) on sipuleucel-T manufacture and immune responses in metastatic castration-resistant prostate c... EJ Small,RS Lance,TA Gardner,... - 《Clinical Cancer Res...
Jong Oh Kim 409Accesses 2Altmetric Explore all metrics Abstract Purpose Abiraterone acetate (ABA), a precursor drug inhibiting androgen biosynthesis (CYP17 inhibitor), is used for treating metastatic castration-resistant prostate cancers. However, it falls under the Biopharmaceutical Classification System ...
The FDA has updated the label for abiraterone acetate plus prednisone to include significant overall survival data from the final analysis of the phase III COU-AA-302 study.